Search by Medical Condition
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for Carcinoid Tumor
- Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
- A Safety Study of 212Pb-Pentixather Radioligand Therapy
- Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
- EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
- Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
- Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
- Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
- Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
- Cabozantinib and Nivolumab for Carcinoid Tumors
- Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
- Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
- Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
- Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
- Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
- Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
- Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
- A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
- Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor
- Avelumab in G2-3 NET
- PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
- Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
- PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
- To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
- MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
- Entinostat Neuroendocrine (NE) Tumor
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
- A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor
- Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
- Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
- A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
- Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
- TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
- A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
- A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
- Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
- FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
- Phase 2 Study of ONC201 in Neuroendocrine Tumors
- Circulating Tumor Cells and Tumor DNA in HCC and NET
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroe
- Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
- A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
- PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
- Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
- Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
- SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors
- Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
- Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
- The MetNET-2 Trial
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
- A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
- Pasireotide Treatment for Neuroendocrine Tumor
- Personalized PRRT of Neuroendocrine Tumors
- Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy
- Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
- Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
- 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
- Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver
- Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib
- Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
- Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
- A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver
- Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
- Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide AutogelĀ® 120 mg
- [68 Ga]-DOTANOC PET/CT in GEP-NETs
- Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
- Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
- Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
- Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor
- Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
- YF476 and Type II Gastric Carcinoids
- Theranostics: 68GaDOTATOC and 90YDOTATOC
- Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
- 18F-FDOPA PET in Neuroendocrine Tumours
- Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
- A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
- 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
- Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
- 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery
- A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus
- Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
- A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
- The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
- A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors
- Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
- Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
- Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
- OPALINE : A Study Of Morbidity And Mortality At 2 Years
- Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
- Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrin Tumor (pNET)
- Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
- GA-68 DOTA-TOC of Somatostatin Positive Malignancies
- 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
- 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
- Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
- Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
- Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
- Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
- Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
- Telotristat Etiprate for Carcinoid Syndrome Therapy
- 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
- Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
- Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
- 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
- Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
- Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
- 68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors
- Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients
- Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
- Randomized Phase III of PRRT Versus Interferon
- Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
- 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- Somatuline Predictive Factors in Acromegaly and NET
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
- VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
- Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
- Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014
- Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors
- TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
- A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
- Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG
- Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
- Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
- TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
- 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
- BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
- Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
- Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Adv
- Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
- Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
- Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
- Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
- Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
- A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
- YF476 and Type I Gastric Carcinoids (Norway)
- A Study of Axitinib in Advanced Carcinoid Tumors
- Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
- Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
- 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
- Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
- YF476 and Type I Gastric Carcinoids
- 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
- Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
- Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
- Pazopanib as Single Agent in Advanced NETs
- Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
- A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
- Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
- 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
- Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
- Study of Everolimus (RAD001) in Combination With Lenalidomide
- Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples
- Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors
- Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
- Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
- Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
- Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
- Study of Panitumumab in the Treatment of Carcinoid Syndrome
- Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
- Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
- RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
- Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
- Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
- Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
- 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)
- AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
- Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
- High Dose Somatostatin Analogues in Neuroendocrine Tumors
- Study of Panobinostat in Patients With Neuroendocrine Tumors
- DOTA-TOC in Metastasized Neuroendocrine Tumors
- Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
- 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
- A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
- Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
- Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
- Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
- Capecitabine and Temozolomide for Neuroendocrine Cancers
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
- RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
- A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
- Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
- An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
- Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
- Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
- Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
- RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe
- Somatuline Autogel Preference and Health Economy Study
- Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
- Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
- Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
- Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
- Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
- Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors
- Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
- Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
- Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
- RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
- Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
- Lithium for Low-Grade Neuroendocrine Tumors
- Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
- Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
- Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
- Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
- Pemetrexed in Patients With Advanced Neuroendocrine Tumors
- Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
- Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
- Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
- Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
- ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
- A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
- Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
- [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
- Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
- Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
- Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
- Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
- Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
- Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
- Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
- Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
- Comparison of Lanreotide AutogelĀ® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
- EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
- Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
- Treatment With SU11248 in Patients With Neuroendocrine Tumors
- EPO906 in Carcinoid and Other Neuroendocrine Tumors
- High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
- Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
- PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
- Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
- Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
- Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
- Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
- Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors